PSTI.TA - Pluristem Therapeutics Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
416.70
-9.60 (-2.25%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close426.30
Open424.90
Bid416.70 x 32000
Ask417.90 x 849800
Day's Range414.90 - 424.90
52 Week Range413.00 - 596.00
Volume200,520
Avg. Volume158,938
Market Cap491.173M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire5 days ago

    New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented additional data from its Phase II clinical study evaluating PLX-PAD for the treatment of Intermittent Claudication (IC) at the 2018 American Heart Association Scientific Sessions in Chicago. The data were presented by Prof. Norbert Weiss, MD, Director of the Vascular Center at the Technical University of Dresden, Germany, and the lead European Principal Investigator for the Phase II IC study.

  • Associated Press9 days ago

    Pluristem: Fiscal 1Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 8 cents per share. The biotechnology company posted revenue of $4,000 in the period. The company's shares closed at $1.18. A year ago, they were trading ...

  • GlobeNewswire9 days ago

    Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fiscal first quarter 2019 ended September 30, 2018 and provided a corporate update. “We were very pleased to announce this quarter on FDA approval of an expanded access program that will provide critical limb ischemia patients who are not suitable for enrollment in our Phase III trial with access to PLX-PAD while the trial is ongoing,” said Yaky Yanay, Co-Chief Executive Officer and President of Pluristem. “During the fiscal first quarter and subsequent period, we continued to make progress advancing our pipeline of novel placenta-based cell therapy products in multiple indications.” Mr. Yanay continued, "We are making good progress in enrolling patients in both ongoing Phase III clinical trials of PLX-PAD in critical limb ischemia (CLI) and the treatment of muscle injury following hip fracture.

  • GlobeNewswirelast month

    Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company will be presenting at four conferences during November: at the BioEurope conference, which is being held November 5–7, 2018 in Copenhagen, at the 15th Annual Vascular Interventional Advances (VIVA) Conference, which is being held November 5-8 in Las Vegas, at the 2018 American Heart Association (AHA) Scientific Sessions, which are being held November 10-12 in Chicago and the Cell and Gene Therapy Manufacturing conference, which is being held November 14-15 in London. At the AHA Scientific Sessions, Prof. Norbert Wiess, the Principal Investigator of the Company’s Phase II intermittent claudication (IC) study, will present detailed results from the study.

  • GlobeNewswirelast month

    U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, and WideTrial Inc., a privately-held third-party sponsor of authorized Expanded Access Programs (EAPs), today announced that the parties have entered into agreement to initiate an FDA-cleared EAP for Pluristem’s cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI). The parties further announced that the FDA has authorized WideTrial to charge payment for the PLX-PAD EAP treatment.

  • GlobeNewswirelast month

    Pluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study

    Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that two-year follow-up data from its Phase I/II clinical study evaluating its allogeneic placenta-derived cell therapy product, PLX-PAD, for the treatment of muscle injury following hip replacement was published in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle. Pluristem also announced that its ongoing Phase III study in the treatment of muscle injury following hip fracture, which is underway in the U.S. and Israel, has been cleared to enroll additional patients in Denmark, Germany and the United Kingdom.

  • GlobeNewswire2 months ago

    Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fourth quarter and fiscal year ended June 30, 2018 and provided a corporate update. “The indications we are pursuing for our novel cell therapy products, PLX-PAD and PLX-R18, target underserved medical conditions for which there are no viable treatment options today,” stated Yaky Yanay, Co-Chief Executive Officer and President of Pluristem.

  • GlobeNewswire2 months ago

    Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy for the Treatment of Graft Failure and Incomplete Recovery Following Hematopoietic Cell Transplantation

    Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s PLX cell therapy for the treatment of graft failure and incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT).

  • What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?
    Simply Wall St.2 months ago

    What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?

    Pluristem Therapeutics Inc (NASDAQ:PSTI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PSTIRead More...

  • Benzinga4 months ago

    Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

    With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners.  The Analyst Analyst  George ...

  • Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?
    Simply Wall St.5 months ago

    Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?

    In this article, I will take a look at Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...

  • Reuters5 months ago

    Israel's Pluristem sees positive results from leg pain study

    Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent ...

  • Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock
    Zacks5 months ago

    Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock

    Investors in Pluristem Therapeutics (PSTI) need to pay close attention to the stock based on moves in the options market lately.

  • Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?
    Simply Wall St.6 months ago

    Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?

    Pluristem Therapeutics Inc’s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The US$156.33M market-cap posted a loss in its most recentRead More...

  • Associated Press6 months ago

    Pluristem: Fiscal 3Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 1 cent per share. The company's shares closed at $1.33. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights ...

  • Benzinga7 months ago

    FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next?

    Pluristem Therapeutics Inc. (NASDAQ: PSTI ), which develops placenta-based cell therapy products, announced Monday that the FDA cleared an investigational new drug application for PLX-R18 cell therapy ...